Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 8/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043424 | 0.75 | QDPR (0.57) | QDPRHTR2CSIGMAR1 | |
| SCHEMBL7804971 | 0.75 | QDPR (0.57) | QDPRHTR2CSIGMAR1PRMT5WDR77 | |
| SCHEMBL27007924 | 0.74 | HTR2C (0.50) | QDPRHTR2CSIGMAR1PDE3BPDE3A | |
| SCHEMBL27007732 | 0.72 | HTR2C (0.48) | QDPRHTR2CSIGMAR1KHK | |
| SCHEMBL3383939 | 0.71 | HTR2C (0.62) | QDPRHTR2CSIGMAR1KHK | |
| SCHEMBL6584726 | 0.71 | QDPR (0.46) | QDPRHTR2CSIGMAR1KHK | |
| SCHEMBL3961889 | 0.70 | SIGMAR1 (0.65) | QDPRHTR2CSIGMAR1KHK | |
| SCHEMBL532892 | 0.70 | HTR2C (0.66) | QDPRHTR2CSIGMAR1KHK | |
| Hydrochloric Acid SCHEMBL6371753 | 0.70 | HTR2C (0.64) | QDPRHTR2CSIGMAR1KHK | |
| Hydrochloric Acid SCHEMBL730625 | 0.69 | HTR2C (0.67) | QDPRHTR2CSIGMAR1KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335660-B2 | Isochroman compounds for treatment of CNS disorders | ELI LILLY AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1458703-B1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | LILLY CO ELI (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | ELI LILLY AND COMPANY | 2005-01-20 | — | — | US | disclosed |
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | QDPR 96/4885HTR2C 14/4885SIGMAR1 55/4885 |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | INA, CNR2, CNR1 | QDPR 488/4885HTR2C 98/4885SIGMAR1 187/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | QDPR 550/4885HTR2C 1211/4885SIGMAR1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.